Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMDW) Revenue (2019 - 2025)

Historic Revenue for Revolution Medicines (RVMDW) over the last 6 years, with Q3 2025 value amounting to -$11.4 million.

  • Revolution Medicines' Revenue changed N/A to -$11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.4 million, marking a year-over-year decrease of 164016.17%. This contributed to the annual value of $11.6 million for FY2023, which is 6726.96% down from last year.
  • As of Q3 2025, Revolution Medicines' Revenue stood at -$11.4 million.
  • Over the past 5 years, Revolution Medicines' Revenue peaked at $15.3 million during Q4 2022, and registered a low of -$11.4 million during Q3 2025.
  • Moreover, its 4-year median value for Revenue was $7.3 million (2022), whereas its average is $5.4 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 20481.38% in 2022, then tumbled by 9515.98% in 2023.
  • Over the past 4 years, Revolution Medicines' Revenue (Quarter) stood at $9.5 million in 2021, then skyrocketed by 62.05% to $15.3 million in 2022, then tumbled by 95.16% to $742000.0 in 2023, then tumbled by 1640.16% to -$11.4 million in 2025.
  • Its last three reported values are -$11.4 million in Q3 2025, $742000.0 for Q4 2023, and $3.8 million during Q2 2023.